The BECN1 Knockout 786-O Polyclonal Cells product offers a CRISPR/Cas9-mediated gene disruption pool in the 786-O human clear cell renal cell carcinoma (ccRCC) line, targeting the BECN1 locus. This polyclonal knockout cell population avoids clonal isolation, providing a heterogeneous yet gene-disrupted model to study Beclin-1 loss-of-function. Beclin-1 is the essential scaffolding subunit of the class III PI3K complex driving autophagosome nucleation and endosomal trafficking.
786-O cells harbor a VHL mutation that stabilizes HIF2??, characteristic of ccRCC, and are widely used to investigate oxygen-sensing defects, metabolic rewiring, and autophagy in kidney cancer. This genetic background offers a disease-relevant system where Beclin-1?Cdependent processes may influence tumor growth and therapeutic response.
Beclin-1 integrates signals from upstream kinases ULK1 and AMPK, which promote autophagy upon energy depletion, while mTORC1 restrains ULK1 activity under nutrient sufficiency. It scaffolds the PI3KC3 core complex with VPS34 (lipid kinase) and VPS15 (serine/threonine kinase), recruiting ATG14 for autophagosome formation or UVRAG for endocytic pathways. Anti-apoptotic BCL2 and BCL-XL bind the Beclin-1 BH3 domain, inhibiting autophagy; this interaction is disrupted by pro-autophagic DAPK phosphorylation or TRAF6-mediated ubiquitination. Active complexes generate PI3P, enabling recruitment of WIPI/DFCP1 effectors, LC3 conjugation to phosphatidylethanolamine, and subsequent degradation of p62/SQSTM1. Additional regulators include AMBRA1, which stabilizes the complex, and Rubicon, which suppresses autophagosome maturation.
In the HIF2??-stabilized 786-O context, autophagy may promote survival under metabolic stress, and Beclin-1??s dual role in tumor suppression and cell homeostasis becomes critical. Knockout of BECN1 can abrogate autophagic flux, revealing whether ccRCC cells rely on autophagy for proliferation, invasion, or resistance to targeted therapies. This model thus enables rigorous dissection of Beclin-1??s autophagy-dependent and -independent tumor-suppressive functions.
Typical experiments include Western blot quantification of LC3-II and p62 accumulation, combined with chloroquine treatment to measure autophagic flux. Co-immunoprecipitation assays using these knockout cells as a negative control validate BCL2 and VPS34 interactions. Functional readouts such as MTT viability, colony formation, and transwell migration/invasion assays determine the impact on tumor cell behavior. High-throughput screens for autophagy modulators or drug sensitizers are also feasible. For further information, please contact Ascent Research.
